Metabolically stabilized oxyalkylene esters and uses thereof

Details Metabolically stabilized oxyalkylene esters and uses thereof Metabolically stabilized oxyalkylene esters and uses thereof

1997-03-11

2000-08-29

Raymond, Richard L.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

424 855, 514 12, 514262, 514374, 514413, 514420, 514423, 514532, 514539, 514544, 514545, 548236, 548432, 548453, 548492, 548539, 560 10, 560 47, 560 48, 560 52, 560 59, 560 66, 560 70, 560 71, 560100, 560102, A61K 31235, A61K 31407, C07C 69025, C07D491052

Patent

active

06110955&

ABSTRACT:
This invention relates to compositions for and methods of treating, preventing or ameliorating cancer and other proliferative diseases as well as methods of inducing wound healing, treating cutaneous ulcers, treating gastrointestinal disorders, treating blood disorders such as anemias, immunomodulation, enhancing recombinant gene expression, treating insulin-dependent patients, treating cystic fibrosis patients, inhibiting telomerase activity, treating virus-associated tumors, especially EBV-associated tumors, modulating gene expression and particularly augmenting expression of a tumor suppressor gene, inducing tolerance to an antigen and treating, ameliorating or preventing protozoan infection. The methods of the invention use metabolically stabilized oxyalkylene esters.

REFERENCES:
patent: 2940855 (1960-06-01), Beavers et al.
patent: 3219630 (1965-11-01), Sidi
patent: 3293220 (1966-12-01), Minami et al.
patent: 3336262 (1967-08-01), Sidi
patent: 3578671 (1971-05-01), Brown
patent: 3720706 (1973-03-01), Lapporte et al.
patent: 3752844 (1973-08-01), Pfister et al.
patent: 3812176 (1974-05-01), Lapporte et al.
patent: 3931412 (1976-01-01), Kensler, Jr. et al.
patent: 4012526 (1977-03-01), Kensler, Jr. et al.
patent: 4105681 (1978-08-01), Bollag et al.
patent: 4123552 (1978-10-01), Kensler, Jr. et al.
patent: 4150137 (1979-04-01), Noda et al.
patent: 4198416 (1980-04-01), Koeda et al.
patent: 4215215 (1980-07-01), Bollag et al.
patent: 4442124 (1984-04-01), Niklaus
patent: 4541944 (1985-09-01), Sanderson
patent: 4545784 (1985-10-01), Sanderson
patent: 4613505 (1986-09-01), Mizushima et al.
patent: 4699925 (1987-10-01), Uchida et al.
patent: 4760057 (1988-07-01), Alexander
patent: 4885311 (1989-12-01), Parish et al.
patent: 4900478 (1990-02-01), Gross
patent: 4916230 (1990-04-01), Alexander
patent: 5025029 (1991-06-01), Perrine
patent: 5158773 (1992-10-01), Gross
patent: 5162573 (1992-11-01), Chiesi et al.
patent: 5185436 (1993-02-01), Villa et al.
patent: 5196567 (1993-03-01), Uchida et al.
patent: 5200553 (1993-04-01), Nudelman et al.
patent: 5216004 (1993-06-01), Perrine
patent: 5569675 (1996-10-01), Rephaeli et al.
patent: 5661179 (1997-08-01), Samid
patent: 5710176 (1998-01-01), Rephaeli et al.
Bhatia, et al., "Induction of Cell Differentiation Potentiates Apoptosis by Sodium Triggered by Prior Exposure to DNA-damaging Drugs", Cell Growth and Differentiation, vol. 6, pp. 937-944, 1995.
Boffa, et al., "Manifold Effects of Sodium Butyrate on Nuclear Function", J. Biol. Chem., vol. 256, No. 18, pp. 9612-9621, 1981.
Bourgeade, et al., "Reorganization of the Cytoskeleton by Interferon in MSV-Transformed Cells", J. of Interferon Res., vol. 1, No. 2, pp. 323-332, 1981.
Brant and Conklin, "Acrolein Diacylates", Chem. Abstracts, vol. 40, p. 3127, 1946.
Carstea, et al., "Analogues of Butyric Acid that Increase the Expression of Transfected DNAs", Biochem. Biophys. Res. Com., vol. 192, No. 2, pp. 649-656, 1993.
Cheng, et al., "Functional Activation of the Cystic Fibrosis Trafficking Mutant deltaF508-CFTR by Overexpression", American Journal of Physiology, vol. 268, No. 4, pp. L615-L624, 1995.
Conway, et al., "Induction of Apoptosis by Sodium Butyrate in the Human Y-79 Retinoblastoma Cell Line", Oncology Research, vol. 7, No. 6, pp. 289-297, 1995.
de Haan, et al., "Effects of Sodium Butyrate on the Synthesis and Methylation of DNA in Normal Cells and Their Transformed Counterparts", Cancer Res., vol. 46, No. 2, pp. 713-716, 1986.
Deschamps, et al., "Inhibition by Salicylic Acid of the Activation and Thus Oxidation of Long Chain Fatty Acids. Possible Role in the Development of Reye's Syndrome", J. Pharm. Exp. Ther., vol. 259, No. 2, pp. 894-904, 1991.
Fishman and Atikkan, "Induction of Cholera Toxin Receptors in Cultured Cells by Butyric Acid", J. Biol. Chem., vol. 254, No. 11, pp. 4342-4344, 1979.
Freneaux, et al., "Inhibition of the Mitochondrial Oxidation of Fatty Acids by Tetracycline in Mice and in Man: Possible Role in Microvesicular Steatosis Induced by This Antibiotic", Hepatology, vol. 8, No. 5, pp. 1056-1062, 1988.
Freneaux, et al., "Stereoselective and Nonstereoselective Effects of Ibuprofen Enantiomers on Mitochondrial beta-Oxidation of Fatty Acids", J. Pharm Exp.Ther., vol. 255, No. 2, pp. 529-535, 1990.
Fromenty, et al., "Tianeptine a New Tricyclic Antidepressant Metabolized by beta-Oxidation of its Hepatanoic Side Chain, Inhibits the Mitochondrial Oxidation of Medium and Short Chain Fatty Acids in Mice", Biochem. Pharm., vol. 38, No.21, pp. 3743-3751, 1989.
Fromenty, et al., "Dual Effect of Amiodarone on Mitochondrial Respiration. Initial Protonophoric Uncoupling Effect Followed by Inhibition of the Respiratory Chain at the Levels of Complex I and Complex II", J. Pharm. Exp. Ther., vol. 255, No. 3, pp. 1377-1384, 1990.
Hague, et al., "Apoptosis in Colorectal Tumor Cells: Induction by the Short Chain Fatty Acids Butyrate, Propionate and Acetate and by the Bile Salt Deoxycholate", Int. J. Cancer, vol. 60, pp. 400-406, 1995.
Ingram and Thomas, "The Electron Impact Inducd Fragmentation of Geminal Dialkanoates", Organic Mass Spectrometry, vol. 12, No. 4, pp. 216-221, 1977.
Le Dinh, et al., "Amineptine, a Tricyclic Antidepressant, Inhibits the Mitochondrial Oxidation of Fatty Acids and Produces Microvesicular Steatosis of the Liver in Mice", J. Pharm. Exp. Ther., vol. 247, No. 2, pp. 745-750, 1988.
Loftsson and Bodor, "Improved Delivery through Biological Membranes IX: Kinetics and Mechanism of Hydrolysis of Methylsulfinylmethyl 2-Acetoxybenzoate and Related Aspirin Prodrugs", J. Pharm. Sci., vol. 70, No. 7, pp. 750-755, 1981.
Los, et al., "Synthesis of Some New Derivatives of 2-Hydroxy and 2-Acetyloxybenzoic Acids", Boll. Chim. Farm., vol. 121, pp. 285-302, 1982.
Man, et al., "Boron Fluoride Catalyzed Addition of Aliphatic Anhydrides to Aldehydes", J. Am. Chem. Soc., pp. 847-848, 1950.
Miller, et al., "Clinical Pharmacology of Sodium Butyrate in Patients with Acute Leukemia", Eur. J. Cancer Clin Oncol. vol. 23, No. 9, pp. 1283-1287, 1987.
Mosher and Kehr, "The Oxidation of Aliphatic Esters with Lead Tetraacetate", J. Am. Chem. Soc., vol. 82, pp. 5342-5345, 1960.
Nielsen and Bundgaard, "Evaluation of Glycolamide Esters and Various Other Esters of Aspirin as True Aspirin Prodrugs", J. Medicinal Chem., vol. 32, pp. 727-734, 1989.
Nordenberg, et al., "Growth Inhibition of Murine Melanoma by Butyric Acid and Dimethylsulfoxide", Exp. Cell Res., vol. 162, pp. 77-85, 1986.
Nordenberg, et al., "Biochemical and Ultrastructural Alterations Accompany the Anti-proliferative Effect of Butyrate on Melanoma Cells", Br. J. Cancer, vol. 55, pp. 493-497, 1987.
Novogrodsky, et al., "Effect of Polar Organic Compounds on Leukemic Cells", Cancer, vol. 51, No. 1, pp. 9-14, 1983.
Nudelman, et al., "Novel Anticancer Prodrugs of Butyric Acid", J. Med. Chem., vol. 35, pp. 687-694, 1992.
Oh, et al., "Convenient Synthesis of Geminal Biscarboxylates:Searching for an Efficient Route to HR 916B", Korean J. Med. Chem., vol. 6, No. 2, pp. 259-262, 1996.
Prasad, "Butyric Acid: A Small Fatty Acid with Diverse Biological Functions", Life Sci., vol. 27, No. 15, pp. 1351-1358, 1980.
Prasad, et al., "Decreased Expressions of c-myc and H-ras Oncogenes in Vitamin E Succinate Induced Morphologically Differentiated Murine B-16 Melanoma Cells in Culture", Biochem. Cell Bio., vol. 68, No. 11, pp. 1250-1255, 1990.
Rabizadeh, et al., "Rapid Alteration of c-myc and c-jun Expression in Leukemic Cells Induced to Differentiate By a Butyric Acid Prodrug", FEBS Lett., vol. 328, No. 3, pp. 225-229, 1993.
Ramain, et al.,"Amineptine Hepatitis: Report of Two Cases", Gastroenterol. Clin. Biol., vol. 5, pp. 469-471, 1981.
Rephaeli, et al., "Butyrate-Induced Differentiation in Leukemic Myeloid Cells: in vitro and in vivo Studies", International Journal of Oncology, vol. 4, No. 6, pp. 1387-1391, 1994.
Riggs, et al., "n-Butyrate Causes Histone Modification in HeLa and Friend Erythroleukaemia Cells", Nature, vol. 268, No.5617, pp. 462-464, 1977.
Roedinger and Millard, "Selective Inhibition of Fatty Acid Oxidation in Colonocytes by Ibuprofen

Affiliated with

Also associated with

Rating

Metabolically stabilized oxyalkylene esters and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Metabolically stabilized oxyalkylene esters and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Metabolically stabilized oxyalkylene esters and uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1250384